HIV advocates are concerned that upcoming changes to Gilead Sciences Inc. s Advancing Access program mean that there will be less money available to local providers for related virus prevention.
Gilead produces PrEP, or pre-exposure prophylaxis, which refers to two antiviral medications under the brand names of Truvada, which was approved by the federal Food and Drug Administration in 2012, and Descovy, which was approved in 2019 that are taken by HIV-negative people to prevent HIV infection.
Through its Advancing Access program, Gilead can provide these medicines free of charge to uninsured individuals. Pharmacies provide a prescription then file claims for reimbursement from Gilead.
Bay Area Reporter :: Gilead to lower PrEP reimbursement to clinics
ebar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ebar.com Daily Mail and Mail on Sunday newspapers.
Nassau DA race heats up as Dems accuse GOP of mischaracterizing bail law
nydailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nydailynews.com Daily Mail and Mail on Sunday newspapers.